dextroamphetamine has been researched along with Recrudescence in 15 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An 18-year-old man with attention-deficit-hyperactivity disorder (ADHD) was prescribed varenicline for smoking cessation." | 3.74 | Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine. ( Moorman, KL; Whitley, HP, 2007) |
| "Hospital charts were reviewed for 66 medical and surgical patients who received dextroamphetamine or methylphenidate to treat a depressive disorder." | 3.67 | Psychostimulant treatment of depressive disorders secondary to medical illness. ( Cassem, NH; Murray, GB; Tesar, GE; Woods, SW, 1986) |
| "Psychotherapy is still the mainstay of treatment; however, relapse rates are high." | 2.44 | Pharmacotherapy of methamphetamine addiction: an update. ( Elkashef, A; Hanson, G; Tiihonen, J; Vocci, F; White, J; Wickes, W, 2008) |
| "Recurrent aphthous stomatitis is a common disorder of the oral mucosa." | 1.43 | Hypofunction of the Sympathetic Nervous System as a Possible Etiologic Cause of Recurrent Aphthous Stomatitis. ( Check, JH; Present, SI, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weisler, RH | 1 |
| Babcock, T | 1 |
| Adeyi, B | 1 |
| Brams, M | 1 |
| Present, SI | 1 |
| Check, JH | 1 |
| Elkashef, A | 1 |
| Vocci, F | 1 |
| Hanson, G | 1 |
| White, J | 1 |
| Wickes, W | 1 |
| Tiihonen, J | 1 |
| Meyer, AC | 1 |
| Rahman, S | 1 |
| Charnigo, RJ | 1 |
| Dwoskin, LP | 1 |
| Crabbe, JC | 1 |
| Bardo, MT | 1 |
| Woolley, JB | 1 |
| Heyman, I | 1 |
| Odum, AL | 1 |
| Shahan, TA | 1 |
| Freeman, WM | 1 |
| Brebner, K | 1 |
| Amara, SG | 1 |
| Reed, MS | 1 |
| Pohl, J | 1 |
| Phillips, AG | 1 |
| Whitley, HP | 1 |
| Moorman, KL | 1 |
| van Kammen, DP | 1 |
| Docherty, JP | 1 |
| Bunney, WE | 1 |
| Doleys, DM | 1 |
| Gupta, S | 1 |
| Ghaly, N | 1 |
| Dewan, M | 1 |
| Fawcett, J | 1 |
| Kravitz, HM | 1 |
| Zajecka, JM | 1 |
| Schaff, MR | 1 |
| Linet, LS | 1 |
| Ando, K | 1 |
| Hironaka, N | 1 |
| Yanagita, T | 1 |
| Woods, SW | 1 |
| Tesar, GE | 1 |
| Murray, GB | 1 |
| Cassem, NH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 4, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of SPD489 in Adults Aged 18-55 With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT00877487] | Phase 4 | 123 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Treatment Study for Frontotemporal Dementia[NCT00088751] | 20 participants | Observational | 2004-07-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The ADHD-RS consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00877487)
Timeframe: Up to 6 weeks
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| SPD489 | 1.6 |
| Placebo | 16.8 |
Treatment failure defined as > or equal to 50% increase in the ADHD-RS with adult prompts total score and a > or equal to 2 point increase in the CGI-S score. (NCT00877487)
Timeframe: Up to 6 weeks
| Intervention | Percent of participants (Number) |
|---|---|
| SPD489 | 8.9 |
| Placebo | 75.0 |
CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill) (NCT00877487)
Timeframe: Up to 6 weeks
| Intervention | Percent of Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Normal, not at all ill | Borderline mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | |
| Placebo | 5.0 | 11.7 | 11.7 | 33.3 | 35.0 | 3.3 | 0 |
| SPD489 | 32.1 | 35.7 | 17.9 | 7.1 | 7.1 | 0 | 0 |
2 reviews available for dextroamphetamine and Recrudescence
| Article | Year |
|---|---|
Pharmacotherapy of methamphetamine addiction: an update.
Topics: Antipsychotic Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; | 2008 |
Behavioral treatments for nocturnal enuresis in children: a review of the recent literature.
Topics: Adolescent; Behavior Therapy; Child; Child, Preschool; Conditioning, Classical; Counseling; Cues; De | 1977 |
1 trial available for dextroamphetamine and Recrudescence
| Article | Year |
|---|---|
Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2014 |
12 other studies available for dextroamphetamine and Recrudescence
| Article | Year |
|---|---|
Hypofunction of the Sympathetic Nervous System as a Possible Etiologic Cause of Recurrent Aphthous Stomatitis.
Topics: Adolescent; Central Nervous System Stimulants; Dextroamphetamine; Female; Humans; Male; Recurrence; | 2016 |
Genetics of novelty seeking, amphetamine self-administration and reinstatement using inbred rats.
Topics: Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Conditioning, Operant; De | 2010 |
Dexamphetamine for obsessive-compulsive disorder.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
D-Amphetamine reinstates behavior previously maintained by food: importance of context.
Topics: Animals; Appetitive Behavior; Central Nervous System Stimulants; Conditioning, Classical; Dextroamph | 2004 |
Distinct proteomic profiles of amphetamine self-administration transitional states.
Topics: Actins; Amphetamine-Related Disorders; Animals; Central Nervous System Stimulants; Cluster Analysis; | 2005 |
Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine.
Topics: Adolescent; Amphetamines; Attention Deficit Disorder with Hyperactivity; Benzazepines; Central Nervo | 2007 |
Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment.
Topics: Acute Disease; Adolescent; Adult; Dextroamphetamine; Dopamine; Female; Humans; Male; Middle Aged; Pi | 1982 |
Augmenting fluoxetine with dextroamphetamine to treat refractory depression.
Topics: Adult; Child of Impaired Parents; Depressive Disorder; Dextroamphetamine; Dose-Response Relationship | 1992 |
CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression.
Topics: Bipolar Disorder; Depressive Disorder; Dextroamphetamine; Dose-Response Relationship, Drug; Drug Syn | 1991 |
Treatment of a refractory depression with a combination of fluoxetine and d-amphetamine.
Topics: Adult; Depressive Disorder; Dextroamphetamine; Drug Combinations; Fluoxetine; Humans; Male; Recurren | 1989 |
Psychotic manifestations in amphetamine abuse--experimental study on the mechanism of psychotic recurrence.
Topics: Animals; Conditioning, Operant; Dextroamphetamine; Disease Models, Animal; Male; Methamphetamine; Mi | 1986 |
Psychostimulant treatment of depressive disorders secondary to medical illness.
Topics: Adjustment Disorders; Adult; Aged; Dementia; Depression; Depressive Disorder; Dextroamphetamine; Fem | 1986 |